Clinical Trials

Sponsor: ECOG-ACRIN

Sponsor Study ID: EAA181

Study Title: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

NCT Number: NCT04566328

Phase: III

Protocol Type: Treatment

Age Group: Adult

Disease Sites: Multiple Myeloma

Study Objectives: This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

If you would like to contact a MUSC study team member to learn more information about this study, click HERE.